

**Table 14-2.2.1.2. Baseline Demographics  
(Safety Analysis Set)**

	Cohort 1 0.001 mg QW (N=11) n(%)	Cohort 2 0.003 mg QW (N=11) n(%)	Cohort 3 0.001 mg QW (N=11) n(%)	Cohort 4 0.003 mg QW (N=11) n(%)	Cohort 5 0.1 mg QW (N=11) n(%)	Cohort 6 0.3 mg QW (N=11) n(%)	Part 1 No Step Dosing Total (N=46) n(%)
Sex - n (%)							
Male	11 (100.0)	11 (100.0)	4 (100.0)	4 (100.0)	10 (100.0)	6 (100.0)	46 (100.0)
Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Ethnicity - n (%)							
Hispanic/Latino	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Not Hispanic/Latino	11 (100.0)	11 (100.0)	4 (100.0)	4 (100.0)	10 (100.0)	6 (100.0)	46 (100.0)
Race - n (%)							
American Indian or Alaska Native	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Asian	3 (27.3)	3 (27.3)	1 (25.0)	1 (25.0)	3 (30.0)	0 (0.0)	11 (23.9)
Black (or African American)	0 (0.0)	0 (0.0)	1 (25.0)	0 (0.0)	0 (0.0)	2 (33.3)	3 (6.5)
Multiple	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Native Hawaiian or Other Pacific Islander	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
White	8 (72.7)	8 (72.7)	2 (50.0)	3 (75.0)	7 (70.0)	4 (66.7)	32 (69.6)
Other	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Page 1 of 2

Data cutoff date: 07DEC2022. N = Number of subjects in the analysis set. n = Number of subjects with observed data. SD = Standard Deviation, Q1 = First Quartile, Q3 = Third Quartile. S = Step Dosing.

Safety analysis set includes all subjects that are enrolled and receive at least 1 dose of AMG 509.

Cohort 7a = C1D1: 0.1 mg, C1D8: 0.3 mg, C1D15: 0.3 mg, C1D22: 0.3 mg; Cohort 7b = C1D1: 0.1 mg, C1D8: 0.3 mg, C1D15: 1 mg, C1D22: 1 mg; Cohort 7c = C1D1: 0.1 mg, C1D8: 0.3 mg, C1D15: 1 mg; Cohort 8 = C1D1: 0.3 mg, C1D8: 1 mg, C1D15: 1 mg, C1D22: 1 mg; Cohort 9 = C1D1: 0.1 mg, C1D8: 0.3 mg, C1D15: 0.75 mg, C1D22: 0.75 mg; Cohort 10 = C1D1: 0.1 mg, C1D8: 1 mg, C1D15: 1 mg, C1D22: 1 mg; Cohort 11 = C1D1: 0.1 mg, C1D8: 0.3 mg, C1D15: 1 mg, C1D22: 1.5 mg; Cohort 12 = C1D1: 0.1 mg, C1D8: 0.3 mg, C1D15: 0.75 mg, C1D22: 1.5 mg; Cohort 13 = C1D1: 0.1 mg, C1D8: 0.3 mg, C1D15: 1 mg, C1D22: 2 mg. Two subjects received reduced dose on C1D8 in Cohort 10.

Program: /userdata/stat/amg509/onc/20180146/analysis/mantl\_pilot/tables/sme\_table\_project/t-dm-base-demo-saf-sd.sas

Output: t14-02-002-001-002-dm-base-demo-saf-sd.rtf (Date Generated:31MAR23:13:37:59) Source: adam.adsl

**Table 14-2.2.1.2. Baseline Demographics  
(Safety Analysis Set)**

	Cohort 1 0.001 mg QW (N=11) n(%)	Cohort 2 0.003 mg QW (N=11) n(%)	Cohort 3 0.001 mg QW (N=11) n(%)	Cohort 4 0.003 mg QW (N=11) n(%)	Cohort 5 0.1 mg QW (N=11) n(%)	Cohort 6 0.3 mg QW (N=11) n(%)	Part 1 No Step Dosing Total (N=46) n(%)
Age (years)							
n	11	11	4	4	10	6	46
Mean	64.1	70.0	69.5	64.8	67.3	66.7	67.1
SD	4.6	6.9	9.0	2.6	6.1	10.8	6.8
Median	64.0	69.0	73.5	65.5	67.5	63.5	67.0
Q1, Q3	63.0, 67.5	67.0, 72.5	68.8, 74.2	64.0, 66.2	63.8, 70.5	59.2, 72.2	63.2, 71.0
Min, Max	53, 69	59, 86	56, 75	61, 67	56, 77	56, 84	53, 86
Age group - n (%)							
18 - 64 years	7 (63.6)	2 (18.2)	1 (25.0)	1 (25.0)	3 (30.0)	4 (66.7)	18 (39.1)
65 - 74 years	4 (36.4)	7 (63.6)	2 (50.0)	3 (75.0)	6 (60.0)	0 (0.0)	22 (47.8)
75 - 84 years	0 (0.0)	1 (9.1)	1 (25.0)	0 (0.0)	1 (10.0)	2 (33.3)	5 (10.9)
>= 85 years	0 (0.0)	1 (9.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.2)

Page 2 of 2

Data cutoff date: 07DEC2022. N = Number of subjects in the analysis set. n = Number of subjects with observed data. SD = Standard Deviation, Q1 = First Quartile, Q3 = Third Quartile. S = Step Dosing.

Safety analysis set includes all subjects that are enrolled and receive at least 1 dose of AMG 509.

Cohort 7a = C1D1: 0.1 mg, C1D8: 0.3 mg, C1D15: 0.3 mg, C1D22: 0.3 mg; Cohort 7b = C1D1: 0.1 mg, C1D8: 0.3 mg, C1D15: 1 mg, C1D22: 1 mg; Cohort 7c = C1D1: 0.1 mg, C1D8: 0.3 mg, C1D15: 1 mg; Cohort 8 = C1D1: 0.3 mg, C1D8: 1 mg, C1D15: 1 mg, C1D22: 1 mg; Cohort 9 = C1D1: 0.1 mg, C1D8: 0.3 mg, C1D15: 0.75 mg, C1D22: 0.75 mg; Cohort 10 = C1D1: 0.1 mg, C1D8: 1 mg, C1D15: 1 mg, C1D22: 1 mg; Cohort 11 = C1D1: 0.1 mg, C1D8: 0.3 mg, C1D15: 1 mg, C1D22: 1.5 mg; Cohort 12 = C1D1: 0.1 mg, C1D8: 0.3 mg, C1D15: 0.75 mg, C1D22: 1.5 mg; Cohort 13 = C1D1: 0.1 mg, C1D8: 0.3 mg, C1D15: 1 mg, C1D22: 2 mg. Two subjects received reduced dose on C1D8 in Cohort 10.

Program: /userdata/stat/amg509/onc/20180146/analysis/mantl\_pilot/tables/sme\_table\_project/t-dm-base-demo-saf-sd.sas

Output: t14-02-002-001-002-dm-base-demo-saf-sd.rtf (Date Generated:31MAR23:13:37:59) Source: adam.adsl